نتائج البحث - "Anne M.L. Jansen"

المساهمون: Medical Oncology, Internal medicine, CCA - Cancer Treatment and quality of life, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Radiology and Nuclear Medicine, Graduate School, APH - Methodology, APH - Personalized Medicine, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

المصدر: Clinical Cancer Research, 28(7), 1402-1411. American Association for Cancer Research Inc.
Clinical Cancer Research, 28(7), 1402-1411. AMER ASSOC CANCER RESEARCH
Clinical Cancer Research, 28, 1402-1411
Hoes, L R, van Berge Henegouwen, J M, van der Wijngaart, H, Zeverijn, L J, van der Velden, D L, van de Haar, J, Roepman, P, de Leng, W J, Jansen, A M L, van Werkhoven, E, van der Noort, V, Huitema, A D R, Gort, E H, de Groot, J W B, Kerver, E D, de Groot, D J, Erdkamp, F, Beerepoot, L V, Hendriks, M P, Smit, E F, van der Graaf, W T A, van Herpen, C M L, Labots, M, Hoeben, A, Morreau, H, Lolkema, M P, Cuppen, E, Gelderblom, H, Verheul, H M W & Voest, E E 2022, ' Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment ', Clinical Cancer Research, vol. 28, no. 7, pp. 1402-1411 . https://doi.org/10.1158/1078-0432.CCR-21-3752Test
Clinical cancer research, 28(7), 1402-1411. American Association for Cancer Research Inc.
Clinical Cancer Research, 28, 7, pp. 1402-1411

مصطلحات موضوعية: Proto-Oncogene Proteins B-raf, Cancer Research, Genomics, THERAPY, TUMORS, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], MODEL, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], All institutes and research themes of the Radboud University Medical Center, Oncology, SDG 3 - Good Health and Well-being, Neoplasms, Humans, Molecular Targeted Therapy, Precision Medicine, BURDEN, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d10b5fcc9b5bf485e35845851e46056dTest
https://doi.org/10.1158/1078-0432.ccr-21-3752Test

8

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma

المؤلفون: Olivier J. van Not, Willeke A.M. Blokx, Alfons J.M. van den Eertwegh, Melissa M. de Meza, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Marion Stevense-den Boer, Astrid A.M. van der Veldt, Marye J. Boers-Sonderen, Anne M.L. Jansen, Michel W.J.M. Wouters, Karijn P.M. Suijkerbuijk

المساهمون: Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Medical Oncology, Radiology & Nuclear Medicine

المصدر: JCO Precision Oncology, 6:e2200018. American Society of Clinical Oncology
JCO Precision Oncology, 6
JCO Precision Oncology, 6:e2200018. AMER SOC CLINICAL ONCOLOGY

مصطلحات موضوعية: Cohort Studies, Nivolumab/therapeutic use, Cancer Research, Oncology, Mutation, Proto-Oncogene Proteins B-raf/genetics, Humans, Melanoma/drug therapy, Immune Checkpoint Inhibitors/pharmacology, Membrane Proteins/genetics, GTP Phosphohydrolases/genetics, Ipilimumab/therapeutic use, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45a14d11d0fa70f6a29c2366447ae5ffTest
https://doi.org/10.1200/PO.22.00018Test

9

Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

المؤلفون: Derk Jan A. de Groot, Anne M.L. Jansen, Mariette Labots, Wendy W.J. de Leng, Hanneke van der Wijngaart, Ann Hoeben, L.J. Zeverijn, Hans Gelderblom, Henk M.W. Verheul, Debbie Robbrecht, L.R. Hoes, Emile E. Voest, Erik van Werkhoven, Daphne L. van der Velden, J. Maxime van Berge Henegouwen, Paul Roepman, Paul Hamberg, Niven Mehra

المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Internal medicine, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, Hematology, Research & Education, Neurology, Medical Oncology, Radiology and Nuclear Medicine, Graduate School, APH - Methodology, APH - Personalized Medicine

المصدر: Clinical Cancer Research, 27(22), 6106-6114. American Association for Cancer Research Inc.
Clinical Cancer Research, 27, 6106-6114
Clinical Cancer Research, 27(22), 6106-6114. AMER ASSOC CANCER RESEARCH
Clinical Cancer Research : an official journal of the American Association for Cancer Research, 27(22), 6106-6114. American Association for Cancer Research Inc.
Van Der Wijngaart, H, Hoes, L R, Van Berge Henegouwen, J M, Van Der Velden, D L, Zeverijn, L J, Roepman, P, Van Werkhoven, E, De Leng, W W J, Jansen, A M L, Mehra, N, Robbrecht, D G J, Labots, M, De Groot, D J A, Hoeben, A, Hamberg, P, Gelderblom, H, Voest, E E & Verheul, H M W 2021, ' Patients with Biallelic BRCA1/2 Inactivation respond to Olaparib treatment across Histologic tumor types ', Clinical Cancer Research, vol. 27, no. 22, pp. 6106-6114 . https://doi.org/10.1158/1078-0432.CCR-21-1104Test
Clinical cancer research, 27(22), 6106-6114. American Association for Cancer Research Inc.
Clinical Cancer Research, 27, 22, pp. 6106-6114

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, MAINTENANCE THERAPY, MULTICENTER, HOMOLOGY-DIRECTED REPAIR, OVARIAN-CANCER, VALIDATION, Olaparib, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], chemistry.chemical_compound, DOUBLE-BLIND, All institutes and research themes of the Radboud University Medical Center, Stable Disease, SDG 3 - Good Health and Well-being, Internal medicine, Clinical endpoint, Medicine, BREAST-CANCER, Loss function, 2-STAGE DESIGNS, business.industry, Wnt signaling pathway, Cancer, medicine.disease, RISKS, chemistry, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], PARP inhibitor, Toxicity, SENSITIVITY, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55c98f524eeae4d08d3446ab9d9820a5Test
https://cris.maastrichtuniversity.nl/en/publications/6d297817-2a7a-4ceb-a790-898d766dde2fTest

10

Novel candidates in early-onset familial colorectal cancer

المؤلفون: C. Richard Boland, Tikam Chand Dakal, Pradipta Ghosh, Thomas P. Slavin, Ajay Goel, Anne M.L. Jansen

المصدر: Fam Cancer

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Cancer Research, Candidate gene, Adolescent, Mutation, Missense, Single-nucleotide polymorphism, 030105 genetics & heredity, Biology, Article, Frameshift mutation, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Exome Sequencing, Genetics, medicine, Humans, Missense mutation, Genetic Predisposition to Disease, Receptor, Notch2, Frameshift Mutation, Exome, Genetics (clinical), Exome sequencing, Aged, DNA Polymerase III, Genetic testing, medicine.diagnostic_test, Microfilament Proteins, Syndrome, Middle Aged, Pedigree, Minor allele frequency, Oncology, rab GTP-Binding Proteins, 030220 oncology & carcinogenesis, Cytochrome P-450 CYP1B1, Female, Colorectal Neoplasms, Genes, Neoplasm

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51b9d93864cc76ff2d0f4cad23daf9afTest
https://doi.org/10.1007/s10689-019-00145-5Test

تنقيح النتائج